Last update May 13, 2019
We do not have alternatives for Lutropin Alfa.
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
Lutropin Alfa is also known as
Lutropin Alfa in other languages or writings:
Lutropin Alfa belongs to this group or family:
Main tradenames from several countries containing Lutropin Alfa in its composition:
|VD||0.16 - 0.23||l/Kg|
|Tmax||9 (4 - 16)||hours|
|T½||10 - 18||hours|
Write us at email@example.com
e-lactancia is a resource recommended by Asociación Pro Lactancia Materna (APROLAM) of Mexico
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM
Luteinizing hormone (LH) is a hormone of the gonadotropin type found normally in the body. It is a glycopolypeptide which is synthesized and secreted by gonadotropic cells from the anterior part of the pituitary gland together with the follicle-stimulating hormone (FSH).
Lutropin alfa is an LH of recombinant origin.
Lutropin alfa is used, accompanied by follitropin (FSH), in infertility treatments to induce ovulation in women with LH deficiency in assisted reproduction programmes.
Afterwards, the human chorionic gonadotropin hormone (hCG) is usually administered to trigger ovulation.
Subcutaneous administration of a daily dose with ovarian ultrasound monitoring or urinary estrogen, up to 35 days according to evolution.
Since the last update we have not found any published data on its excretion in breast milk.
Its high molecular weight makes its excretion in breastmilk very unlikely.
Due to its glyco-proteic nature it is inactivated in the gastrointestinal tract, not being absorbed, (oral bioavailability is practically zero), which impedes transfer to infant plasma from breastmilk, except in premature babies and the immediate neonatal period, when there may be more intestinal permeability.
Although it causes an increase in the secretion of estradiol by the follicles (AEMPS 2005), there is no proof that its estrogenic effects decrease milk production.
BREASTFEEDING and INFERTILITY TREATMENTS
In assisted reproduction treatments (ART) for infertility, two issues must be taken into account:
1. The possible effects of ART on the infant or breastfeeding.
The medication used, in general, does not interfere with breastfeeding and does not affect the infant, who in these cases is usually older than 6 months and even 1 or 2 years old.
2. The possible interference of breastfeeding with ART.
Breastfeeding, especially frequent, could hinder ovulation. This is the main reason why assisted reproduction services recommend suspending breastfeeding before starting treatment which is usually emotionally costly and, often, also from a financial perspective.
To date, there is no published data that proves that breastfeeding is incompatible with assisted reproduction techniques (ART).
See below the information of these related products: